What is Vellore grade IV in the context of tuberculous meningitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vellore Grade IV in Tuberculous Meningitis

Vellore grade IV is the most severe clinical grade in the Vellore grading system for tuberculous meningitis with hydrocephalus, characterized by profound neurological deterioration with decerebrate or decorticate posturing and is associated with extremely poor outcomes and high mortality rates. 1

Understanding the Vellore Grading System

The Vellore grading system is specifically used for clinical assessment of patients with tuberculous meningitis (TBM) and hydrocephalus. It consists of four grades:

  • Grade I: Best clinical grade - patient alert and oriented with minimal neurological deficits
  • Grade II: Moderate impairment
  • Grade III: Severe impairment
  • Grade IV: Worst grade - profound neurological deterioration with decerebrate/decorticate posturing

Clinical Significance of Vellore Grade IV

Patients with Vellore grade IV TBM with hydrocephalus have:

  • Extremely poor prognosis
  • High mortality rates (reported as high as 60%) 2
  • Limited benefit from surgical interventions 1
  • Questionable utility of neurosurgical procedures 1

Management Considerations for Grade IV Patients

The management of Vellore grade IV patients is challenging:

  • Surgical intervention: The utility of ventriculoperitoneal (VP) shunt placement or endoscopic third ventriculostomy (ETV) in grade IV patients is debatable due to poor outcomes 1
  • Mortality risk: Surgery for grade IV patients is associated with high mortality (up to 60%) 2
  • Good outcome rates: Only about 20% of grade IV patients achieve good outcomes even with intervention 2

Treatment Approach

Despite poor prognosis, treatment should still be initiated:

  1. Antitubercular therapy: Immediate initiation of the standard regimen as recommended by the American College of Physicians and Infectious Diseases Society of America 3

    • Initial phase (2 months): Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol
    • Continuation phase (7-10 months): Isoniazid and Rifampicin
  2. Adjunctive corticosteroids: Strongly recommended for all TBM patients 3

    • Dexamethasone (12 mg/day) or Prednisolone (60 mg/day), tapered over 6-8 weeks
  3. Management of hydrocephalus:

    • Medical management with dehydrating agents and steroids may be attempted first
    • Surgical intervention has questionable benefit in grade IV but may be considered on a case-by-case basis

Prognostic Factors

Several factors contribute to poor outcomes in grade IV patients:

  • Seizures (significantly increased hazard ratio for poor outcomes) 4
  • Low Glasgow Coma Scale scores 4
  • High cerebrospinal fluid cell count 4
  • Delayed initiation of treatment 5

Important Caveats

  • The decision for surgical intervention in grade IV patients should be carefully weighed against the high risk of mortality
  • Early diagnosis and treatment of TBM before progression to grade IV is crucial for improving outcomes
  • Even with optimal management, grade IV patients have significantly worse outcomes compared to those with less severe grades
  • Hydrocephalus occurs in up to 85% of children with TBM and is generally more severe in children than adults 1

The Vellore grading system has been validated by multiple studies and serves as an important prognostic tool in the management of TBM with hydrocephalus, with grade IV representing the most severe form with the poorest prognosis.

References

Guideline

Treatment of Tubercular Meningitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical Outcome of Tuberculous Meningitis with Hydrocephalus - A Retrospective Study.

The Malaysian journal of medical sciences : MJMS, 2021

Related Questions

What is the prognosis for a patient with Tuberculosis (TB) meningitis and altered sensorium?
Should anti-tubercular therapy (ATT) be considered in a patient with cerebral venous thrombosis (CVT) and venous hemorrhagic infarct, and cerebrospinal fluid (CSF) studies showing elevated protein, low sugar, and lymphocytic predominance, but a normal adenosine deaminase (ADA) level, given a concern for tuberculous meningitis?
What is the most appropriate treatment for a patient with signs and symptoms of meningitis, low cerebrospinal fluid (CSF) glucose, elevated CSF protein, and predominant lymphocytes?
When can treatment be stopped for a patient with disseminated tuberculosis (TB) who has taken anti-tubercular treatment (ATT) with Rifampicin (Rifampicin), Pyrazinamide (PZA), Ethambutol (Conbutol) for 12-13 months, had a 2-3 month gap, and then took Akurit 4 (Rifampicin + Isoniazid + Pyrazinamide + Ethambutol) for 6 months, with abdominal and brain TB involvement?
After how long can clinical improvement be expected after starting Antitubercular Therapy (ATT) in tubercular meningitis?
What is the guideline for managing hiatal hernia?
What is the treatment approach for atrophic gastritis?
What are the essential things to know for a bariatric clinic day?
Does Furosemide offer any benefit in Acute Respiratory Distress Syndrome (ARDS)?
What is the recommended treatment regimen for a patient with type 2 diabetes, especially those with established cardiovascular disease, using a Glucagon-like peptide-1 (GLP-1) agonist?
What is the definition and treatment of severe paracoccidioidomycosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.